CA2071974C - Vaccine compositions for fish - Google Patents

Vaccine compositions for fish Download PDF

Info

Publication number
CA2071974C
CA2071974C CA002071974A CA2071974A CA2071974C CA 2071974 C CA2071974 C CA 2071974C CA 002071974 A CA002071974 A CA 002071974A CA 2071974 A CA2071974 A CA 2071974A CA 2071974 C CA2071974 C CA 2071974C
Authority
CA
Canada
Prior art keywords
fish
vaccine
oil
emulsion
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002071974A
Other languages
French (fr)
Other versions
CA2071974A1 (en
Inventor
Michael Edward John Barratt
Dennis Leadbeater
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOOKER AQUACULTURE Ltd
Original Assignee
BOOKER AQUACULTURE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2071974(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BOOKER AQUACULTURE Ltd filed Critical BOOKER AQUACULTURE Ltd
Publication of CA2071974A1 publication Critical patent/CA2071974A1/en
Application granted granted Critical
Publication of CA2071974C publication Critical patent/CA2071974C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/80Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0208Specific bacteria not otherwise provided for
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Lead Frames For Integrated Circuits (AREA)

Abstract

An oral composition for fish or similar aquatic creatures comprises a stable viscous water-in-oil emulsion containing a vaccine against fish disease, the emulsion being carried on fish feed particles. The oral composition can be administered to fish in a non-labour-intensive manner and causes no stress to the fish, in complete contrast to conventional vaccine administration by parenteral injection. Moreover, the oral composition can substantially reduce the minimum effective vaccine dose.

Description

. ..Vbr~ 92106599 PCT/GB91/01828 VACCINE COMPOSITIONS FOR FISH
IO
This invention relates to compositions useful for oral administration of sensitive materials such as vaccines to aduatic animals, especially fish.
The intensive rearing of fish such as salmon, which today is practised vn a wide scale, suffers from the disadvantage that the entire stock of fish in a facility may become infected with disease. The commercial consequences of a serious disease outbreak can be enormous. Several well-recognised fish diseases are causing severe problems in the fish farming industry.
Examples are bacterial-kidney disease, caused by ~ten~bacterium salmo inarum; enteric redmouth, caused by Yersinia ruc a '; and Vibriosis, caused by various strains of Vibrio, notably V anauillarum and V salmonicida.
Currently, the most significant disease, at least as far 3o as the farming in T3orthern Europe of Atlantic salmon Salma salary is concerned, is furunculosis; this is caused by the bacterium Aeromonas salmo~i,cida.

PC'I'/GB91/01~2~ ,.,~
i~t~ 92/06599 The desirability of immunising farmed fish against such diseases has long been recognised. However, technical progress in this area has been slow. This applies both to the effectiveness of the commercially available vaccines (a wholly effective vaccine for salmon against furunculosis has yet to be developed), and also to the means by which such vaccines are administered to the fish. Traditionally, administration of vaccines to fish has either been by immersion (which j.s wasteful as well as of limited efficacy), or by injection. Although injection to of individual fish provides a sure way of delivering a vaccine, it suffers from the disadvantages that it is very labour-intensive, and moreover the handling and injection cause considerable stress to the fish, and can precipitate disease problems or at least cause temporarily retarded 1~
growth. Usually fish are anaesthetised prior to injection. .
There is a clear commercial need for a vaccine delivery system for fish which is less labour-intensive, and which causes little or no stress to the fish.
For some while it has been recognised that an oral delivery system, in which a vaccine is administered to the fish either as part of the regular diet or in a composition administered together with the regular diet, would be beneficial. Reported experiments involving attempted oral administration of fish vaccines have yielded inconsistent results, and no effective oral 3o vaccine has yet become available commercially. Particular problems recognised in the oral route are: possible loss of or damage to essential vaccine components during manufacture of the composition; possible loss of water-soluble vaccine components in the aqueous environment ~n which the fish live; and possible '.WO 92/0699 PCTlGB91l01828 degradation of the vaccine within the intestine of the fish before the vaccine has induced a protective response.
By the present invention we provide a particulate composition for oral administration to aquatic creatures, especially fish, comprising a water-in-coil emulsion containing a sensitive agent such as a vaccine or the like, the emulsion being carried on a solid edible carrier material, preferably particles of a feed-stuff appropriate to for the aquatic creatures.
The skilled reader will readily appreciate that the invention can be adapted far use with aquatic creatures other than true fish, for example crustacea such as prawns, shrimps, lobsters and crabs, and molluscs such as oysters. For convenience,. the invention will be described in relation to fish, and the term "fish°' should be understood as encompassing other aquatic life farms that may benefit from the oral administration of vaccines and 2o the like. Bxamples of true fish that are reared on a substantial scale in captivity in various parts of the world are: Atlantic salmon, Pacific salmon, rainbow trout, brown trout, catfish, halibut, turbot, carp and tilapia.
Generally, the sensitive agent will be water-soluble rather than oil-soluble, and hence dispersed in the aqueous phase of the emulsion. The emulsion should contain sufficient of the sensitive agent to provide the 3o desired effect, eg. an effective immune response, when the composition is administered to the fish.
Preferably the emulsion is applied to particulate fish feed~that is nutritionally deficient in oil.

W~ 921U65~9 ~ ~ ~ ~ ~ ~ ~ PCT/GB91/01828 Preferably the emulsion comprises a water: oil mixture containing not more than about 70% by weight water. More preferably, the water content is not greater than about 65% by weight. Nevertheless, the emulsion must contain sufficient water to act as a carrier for the water-soluble agent, and a particularly preferred water: oil weight ratio range is 6:4 to 4:6.
Preferably the emulsion comprises at least about 1%
to by weight of the final composition. More preferably, the emulsion comprises at least about 2%, and ideally at least about 3%, by weight of the composition. Generally, the amount of emulsion is not greater than about 10%~by weight.
The emulsion should have a viscous consistency, ie.
creamy and flowable, to enable it to be applied uniformly to the particulate carrier.
2o The carrier should be relatively dry and non-oily so that the applied emulsion can be absorbed, at least partially, by the particles. Preferably the particulate carrier is nn-oiled feed in granular or pelletted form.
The composition of the feed is not critical to the invention, as long as the formulation is appropriate for the fish to which the composition is to be fed, and at the time of adding the emulsion the particles do not contain oil ar other fluid ingredients in such amounts that the emulsion cannot be absorbed by the particles. After the 3o aPPlication of the emulsion, the particles should still be sufficiently dry and free-flowing to be handled in the same manner as conventional fish feed. Typical fish feeds are high in protein, and are conventionally based an fish meal with added components such as cereals, and ail as an energy source. Fish meal naturally contains a certain ?p~yf~'~~
W~0 92/06599 PCT/GB91/01828 amount of ail, but usually this needs to be boosted for nutritional reasons. The additional oil is usually added to the granules or pellets after these have been formed;
the oil-deficient material is herein termed "un-oiled'°.
The size of fish feed pellets varies widely, depending on the type and age of the fish; for salmon the pellets typically have a diameter from about Z to about 6mm, with pellets of about 3mm being appropriate at the smolt stage.
Fish feeds can also contain minor components such as vitamins, minerals, preservatives and pigments.
to Alternatively, non-feed carriers can be used, but these should provide final compositions that are perceived by the fish as normal feed, otherwise the fish may ignore ar reject the composition. Fish tend to be very critical in Z5 accepting feed particles, and many factors such as size, shape, colour and density, which all affect the "behaviour" of the particles in water, can be very influential. A composition of the invention should therefore be made to have physical properties as similar 2o as passible to those of the normal feed to which the fish are accustomed.
The emulsion should be sufficiently stable to protect the aqueous phase for a time sufficient to enable the 25 composition to be produced and administered to the fish.
In general, the emulsion should not °'crack'°, ie. separate into distinct aqueous and oil phases, in less than one week. Preferably, the emulsion is stable for at least one month.
The oil is preferably a neutral oil, because the presence of free fatty acids can sometimes interfere with the formation of an adequately stable emulsion.
Preferably, the level of free fatty acids should b~ not greater than about 5a by weight of the oil, and ideally W~ 92/06599 PCTlGB91/01~2~ '. ~ ' not greater than about 3~. Preferred oils are whole fish body oil and neutral marine oil. If desired, the emulsion ' can incorporate an antioxidant such as butylated hydroxytoluene or ethoxyquin. ' The emulsifier should be food grade, and is preferably a lecithin. An ideal emulsifier is soya lysolecithin (a modified phospholipid) and examples are available commercially from Unimills BV under the trade name "Bolek". Generally, the emulsifier will comprise from about 0.1 to about 5% by weight of the total emulsion.
The emulsion can be prepared by blending the oil and aqueous phases, generally at ambient temperature, using a homogeniser. In-line homogenising equipment is preferred.
Preferably the components can be recycled two: or more times through the homogeniser if desired.
The invention also provides a process for the preparation of an orally administrable composition for fish, wherein a stable water-in-oil emulsion containing a sensitive agent such as a vaccine, is applied to a particulate feedstuff, preferably by pan-coating or the like.
In a preferred embodiment of the invention, additional oil, eg. from about 1 to about 3% by weicJht, is applied to the particulate composition after the aPPlication thereto of the emulsion. This can also be achieved by pan-coating.
An important aspect of the invention is the use of an oral delivery system to reduce the total effective administered dose level of a vaccine that would otherwise 7 _ need to be administered by a non-oral route (generally by injection or immersion) in a substantially higher total dose. We have found that administration of a vaccine in a composition according to the invention surprisingly enables an effective protective response in fish to be achieved at a much lower dose level. In some circumstances, a 10-fold reduction in the effective dose level can be achieved.
l0 For example, we have conducted trials with a commercially-available furunculosis vaccine ("Furogen")~
which is recommended for single administration by parenteral injection at a dose level of 0.1 ml per fish.
We have administered this commercially-available vaccine orally to salmon using a composition of the invention. We have found that a total dose level of only 0.001 ml "Furogen" per fish, administered orally over a ten-day period, provided protection at least as effective as the single recommended 0.1 ml dose administered by injection.
2o In contrast to the injection route, oral administration of the vaccine in accordance with the invention did not cause any stress to the fish, and could be conducted as part of their normal feeding regime.
Although the theory behind the effectiveness of the invention is not yet fully understood, we believe that the oral administration of a furunculosis vaccine in accordance with the invention promotes a cellular response in the fish, which leads to enhanced protection. This 3o protection seems unrelated to the quantity of antibodies within the circulation system of the fish. Administration of the same vaccine by injection may lead to enhanced circulating antibody levels, but apparently its impact at the cellular level has not been studied.
:35 T/ 4~.~ t n ~n !V0 92/06599 ~ ~ ° ~ '' 3 ~ fCT/GB91/01828 _ g _ We believe that the oil in a composition of the invention protects the antigenic components of the vaccine from degradation in the upper acidic regions of the gut of the fish, while allowing the antigenic components to be released in the lower alkaline regions where the oil is digested enzymatically.
An oral composition of the invention, containing a vaccine, can be used in place of conventional inject:able and/or immersion vaccines. Alternatively, a combination 1o of routes of administration can be employed, for example by using the oral route to provide a basic level of protection which can be boosted at an appropriate occasion (eg. when fish are moved or counted, or at a time of greater perceived infection risk) by a supplementary injection or immersion.
Although it is envisaged that a composition of the invention will generally be administered to farmed fish, at can also be distributed "in the wild" to reduce the incidence of fish disease in the natural environment, so benefiting the indigenous fish population and enhancing global fish resources.
z5 The oral composition of the invention can be prepared "on the spat" for immediate administration to fish.
Alternatively, a composition of the invention can be prepared and packaged in any manner conventionally uses for commercially-available fish feeds, for example in 3o grease-proof sacks, and supplied as a commercial product.
The shelf-life of the composition can be enhanced, if necessary, by the incorporation of preservatives, eg. in ' the applied emulsion.

_ g _ The invention can be used to administer any fish vaccine that can induce an immune response via the gut.
For example, the vaccine can be a simple bacterin composition, ie. a killed whole culture of an infective organism, or an extract of a killed culture. The vaccine s can comprise toxoided components, ie, toxic factors associated with the infective organism which have been treated, eg. by chemical means such as formaldehyde or glutaraldehyde treatment, to reduce their toxic effect without seriously impairing their antigenic properties.
Where appropriate, the vaccine can comprise live organisms,.preferably attenuated, eg. by controlled culture or by genetic manipulation. The active components of the vaccine can include, or indeed can consist entirely is of, factors originally identified in the disease-causing organism but subsequently produced for the purpose of the vaccine by expression in genetically-modified organisms such as E.coli.
By way of example only, a composition in accordance with the invention can be made as follows.
Example 1 25 An approximately 1:1 mixture of whole fish body oil and diluted aqueous "Furogen" injectable vaccine (an aqueous composition containing a bacterin derived from killed Aeromonas organisms) was blended by multiple passes through an ultrasonic homogeniser, to form a stable creamy ;o water-in-oil emulsion, with the aid of 3~ (total weight) of "Bolek~K" lecithin emulsifier. "Bolek K" may no longer be commercially available, but other lecithin emulsifiers from the "Bolek" range, such as "Bolek M", can be regarded as identical for the practical purposes of this invention.
3s "Furogen" is available commercially from Aquahealth i fVO 92/06599 ~ ~ ~ ~ ~ ~ PC'f/G~91/01828 ~.' Limited, Canada and supplied in two formulations: for parenteral injection and for immersion.
The emulsion was soaked into un-oil.ed conventianal extruded 3mm diameter fish feed pellets (based on fish meal and cereal), by pan-coating, using 5% emulsion by weight of the feed. An additional 2.5% fish oil by weight was added subsequently to the feed by the same method.
Fish normally consume 1-3% body weight/day, and the quantity of °'Furogen" was adjusted, by dilution with crater, to provide a total of about 0.001 ml of the commercially-supplied injectable composition over a 10-day trickle feed period.
The resulting composition was physically indistinguishable from conventional oiled fish feed pellets, and could be handled and fed to fish.in any conventional manner, eg. by hand or by mechanical feeders.
sample 2 Trials in Atlantic salmon Salmo salary were conducted as follows, using oral compositions made as in 2S Example 1, with a control group of fish receiving the commercially-available injectable composition.
Groins and treatment 3o All fish were 1990 smolts from a commercial salmon hatchery.
a) 1000 fish; composition of Example 1 containincf "Furogen" immersion vaccine formulation @ 0.1 ml/fish*.

~~~1~~ 9 '' 'R'~O 92/06599 1P~C.'T/GB91101828 b) 1000 fish; composition of Example 1 containing "Furogen" injectable vaccine formulation @ 0.1 ml/f ish*.
c) 1000 fish; composition of Example Z containing "Furogen" immersion vaccine formulation @ 0.01 ml/fish*.
d) 1000 fish; composition of Example 1 containing ''Furogen" immersion vaccine formulation @ 0.001 lfl ml/fish*.
Control: 750 fish receiving a single dose of °'Fur~gen°' by injection @ 0.1 ml/fish.
*Total received on average per fish over a lo-day feeding period.
Method To identify the groups, all fish were marked using a panjetter and Alcian blue dye ~4%) before the beginning of the experiment.
Fish were fed their respective vaccines over a 10-day period in separate tanks, with a common water supply.
The fish were sample weighed and cultured far A.salmonicida. Low-level infection was already present, 3o representing a typical on-farm situation. Further challenge was natural, from the local water supply.
The results are shown in Table 1, and indicate the percentage cumulative mortality of the trial groups over a 35 one-month period commencing from the start of vaccination.

13'O 92/06599 ~ ~ ~ ~ ~ ~ ~~ PCTlG1391/~01828 ,., ..

These results demonstrate that the oral route is an effective delivery system, and produces results at least as good as the injection raute. Indeed, the results indicate that the oral route can enable lo~rer administered vaccine levels to be used and at the same time induce enhanced protection.
Table 1 Composition Dose (mljfish) Mortality ~~~) Control 0.1 15.0 a~ 0.1.. 12.6 b) 0.1 7.0 c, 0.01 12.8 d~ 0.001 1.4 y

Claims (7)

CLAIMS:
1. A composition for oral administration to fish, comprising a water-in-oil emulsion containing a vaccine that can induce an immune response via the gut, the emulsion being carried on a particulate feedstuff, and wherein said water-in-oil emulsion comprises a water:oil mixture of 6:4 to 4:6 by weight.
2. A composition according to claim 1, wherein the emulsion is carried on a particulate fish feed that is nutritionally deficient in oil.
3. A composition according to claim 1 or claim 2, wherein the vaccine is a vaccine against furunculosis.
4. A composition according to any one of claims 1 to 3, wherein the emulsion comprises at least 1% by weight of the composition.
5. A process for the preparation of the composition of any one of claims 1 to 4, said process comprising blending a mixture of oil, water and a vaccine to form a water-in-oil emulsion containing a vaccine, and applying said water-in-oil emulsion containing a vaccine to a particulate feedstuff.
6. A process according to claim 5, wherein additional oil is applied to the particulate feedstuff after the emulsion is applied to the particulate feedstuff.
7. Use of a water-in-oil emulsion containing a vaccine, wherein said water-in-oil emulsion comprises a water:oil mixture of 6:4 to 4:6 by weight, in the preparation of a medicament for treating bacterial kidney disease, enteric redmouth, vibriosis and furunculosis in fish.
CA002071974A 1990-10-22 1991-10-18 Vaccine compositions for fish Expired - Lifetime CA2071974C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB90311541.8 1990-10-22
EP90311541 1990-10-22
PCT/GB1991/001828 WO1992006599A2 (en) 1990-10-22 1991-10-18 Vaccine compositions for fish

Publications (2)

Publication Number Publication Date
CA2071974A1 CA2071974A1 (en) 1992-04-23
CA2071974C true CA2071974C (en) 2006-05-23

Family

ID=8205583

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002071974A Expired - Lifetime CA2071974C (en) 1990-10-22 1991-10-18 Vaccine compositions for fish

Country Status (5)

Country Link
CA (1) CA2071974C (en)
GB (1) GB2255909B (en)
IE (1) IE65568B1 (en)
NO (1) NO314536B1 (en)
WO (1) WO1992006599A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US6013255A (en) * 1994-04-18 2000-01-11 Gist-Brocades B.V. Stable water-in-oil emulsions
EP0703730B1 (en) * 1994-04-18 2001-12-12 Dsm N.V. Stable water-in-oil emulsions
US7317142B2 (en) * 2002-12-13 2008-01-08 Prodi Gene, Inc. Immunization of fish with plant-expressed recombinant proteins
NO322697B1 (en) * 2005-03-18 2006-11-27 Fishfeed As Process for the preparation of fish feed with high content of water and lipid.
ITFI20090244A1 (en) * 2009-11-21 2011-05-22 Francesca Serdoz NANO-LIQUID LIPID SYSTEMS FOR VEHICULAR ACTIVE AND NUTRACEUTICAL PRINCIPLES IN FEEDS FOR LIVESTOCK USE.
CU24075B1 (en) * 2011-08-26 2015-01-29 Ct De Ingeniería Genética Y Biotecnología VACCINAL COMPOSITION THAT INCLUDES THE ACTIVATING PEPTIDE OF THE PITUITARY CYCLING ADENYLATE AS A MOLECULAR ASSISTANT.
DK179072B1 (en) * 2012-05-08 2017-10-09 Novartis Tiergesundheit Ag New Treatment
CN105830977B (en) * 2016-04-12 2018-04-24 中国水产科学研究院淡水渔业研究中心 A kind of cultural method for improving top grade commodity crab ratio

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492400A (en) * 1968-03-22 1970-01-27 Us Interior Oral immunization of salmonids against furunculosis,and alum-precipitated aeromonas salmonicida antigenic fraction therefor
US3862313A (en) * 1974-01-17 1975-01-21 Us Interior Vibrio vaccine and immunization
JPS6011012B2 (en) * 1975-10-28 1985-03-22 クミアイ化学工業株式会社 Growth promoters for pigs and poultry, and egg production promoters for poultry
DD127010A1 (en) * 1976-04-05 1977-08-31
DE3224365C2 (en) * 1982-06-30 1985-09-12 Edmund 8901 Wehringen Müller Floatable carrier for pharmaceutical products and the like
DD259135A1 (en) * 1986-07-22 1988-08-17 Loeffler Friedrich Inst PROCESS FOR PRODUCING PERORIALIA FOR FISH
US4938956A (en) * 1987-04-01 1990-07-03 International Minerals & Chemical Corp. Synergistic immunostimulating composition and method
CA1330303C (en) * 1989-02-20 1994-06-21 Libor Henry Nikl Composition and process to enhance the efficacy of a fish vaccine

Also Published As

Publication number Publication date
NO922445L (en) 1992-08-19
WO1992006599A2 (en) 1992-04-30
WO1992006599A3 (en) 1992-07-09
IE913644A1 (en) 1992-04-22
CA2071974A1 (en) 1992-04-23
GB2255909A (en) 1992-11-25
GB9212207D0 (en) 1992-09-09
IE65568B1 (en) 1995-11-01
NO922445D0 (en) 1992-06-19
GB2255909B (en) 1994-08-03
NO314536B1 (en) 2003-04-07

Similar Documents

Publication Publication Date Title
Langdon Microparticle types for delivering nutrients to marine fish larvae
Webster et al. Use of soybean meal and distillers grains with solubles as partial or total replacement of fish meal in diets for channel catfish, Ictalurus punctatus
Ajiboye et al. A perspective on the ingestion and nutritional effects of feed additives in farmed fish species
JP6703954B2 (en) Microencapsulated aquaculture feed
AU2021104909A4 (en) Use of alpha lipoic acid as a feed additive for aquatic animals
Appelbaum Rearing of the Dover sole, Solea solea (L), through its larval stages using artificial diets
CA2071974C (en) Vaccine compositions for fish
Merchie et al. The effect of supplemental ascorbic acid in enriched live food for Clarias gariepinus larvae at startfeeding
Merchie et al. Evaluation of vitamin C-enriched Artemia nauplii for larvae of the giant freshwater prawn
EP0848955B1 (en) Anti-stress agent for animals comprising an ascorbic acid derivative
Chamberlain Frontiers in shrimp nutrition research
Herman Prevention and control of fish diseases in hatcheries
Conklin Vitamin requirements of juvenile penaeid shrimp
CA2348504C (en) Composite, particulate feed for fry or for larvae of other marine organisms and method of manufacturing the starting feed
JP3549217B2 (en) Improved fish farming
JPH08509372A (en) Compositions for administration to coccidiosis animals
Roa et al. Use of rehydratable extruded pellets and attractive substances for the weaning of sole (Solea vulgaris)
JP2000281568A (en) Agent for preventing and curing parasite
Craig et al. Growout and broodstock nutrition
AU2005244701A1 (en) Feedstuff and gamma-aminobutyric acid feeding method
Serezli et al. The effect of vitamin E on black sea trout (Salmo labrax) broodstock performance
US4666891A (en) Method of stimulating animal growth by administering feed and inosine complex
JP3520339B2 (en) How to cultivate puffer fish
da Silva et al. Nutrition and dietary selection
Webster et al. Nutrition and fish health

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry